All In Biotech

Drug Trial Radar · NCT05351346

Genotype-guided Treatment in DLBCL

A Study Comparing the Efficacy and Safety of Genotype-guided R-CHOP-X Versus R-CHOP in Patients With Diffuse Large B-Cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Mar 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 1,100 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,100

Planned (sponsor's estimate)

Start

Jun 1, 2022

Primary completion

Jun 1, 2026

Study completion Jun 1, 2026

Sponsor

Lead sponsor
Ruijin HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
West China Hospital; Qilu Hospital of Shandong University; Shanghai Jiao Tong University Affiliated Sixth People's Hospital; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; The Second Hospital of Anhui Medical University; Zhongda Hospital; The First Affiliated Hospital of Soochow University; China-Japan Friendship Hospital; Tongji Hospital; Beijing Hospital; The Second Affiliated Hospital of Dalian Medical University; Zhujiang Hospital; The First Affiliated Hospital of Anhui Medical University North District; Hunan Cancer Hospital; Liaoning Cancer Hospital & Institute; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School; Cancer Hospital Affiliated to Xinjiang Medical University; The First Affiliated Hospital of Xiamen University; The First Affiliated Hospital of Nanchang University; LanZhou University; Central South University; The Affiliated Hospital of Xuzhou Medical University; Yunnan Cancer Hospital; Henan Cancer Hospital; Fujian Medical University Union Hospital; The First Hospital of Jilin University; The First Affiliated Hospital of Anhui Medical University; Gansu Cancer Hospital; The First Affiliated Hospital of University of Science and Technology of China; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine; Second Affiliated Hospital of Xi'an Jiaotong University; First Affiliated Hospital Xi'an Jiaotong University; RenJi Hospital; Shandong Cancer Hospital and Institute; Affiliated Cancer Hospital of Harbin Medical University; First Affiliated Hospital of Chongqing Medical University; Fudan University; Chinese Academy of Medical Sciences; Affiliated Hospital of Nantong University; The First People's Hospital of Yunnan; Shanxi Province Cancer Hospital; Fifth Affiliated Hospital of Guangzhou Medical University; Beijing Tongren Hospital; First Affiliated Hospital of Harbin Medical University; The Third Affiliated Hospital of Wenzhou Medical University; Harbin Institute of Hematology; The First Affiliated Hospital of Guangzhou Medical University; Affiliated Hospital of Guilin Medical College; Air Force Military Medical University, China; Affiliated Zhongshan Hospital of Dalian University; Yantai Yuhuangding Hospital; The First Affiliated Hospital of Zhengzhou University; Peking University Third Hospital
First posted
Apr 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of genotype-guided targeted agents plus rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP-X) versus rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with diffuse large B-cell lymphoma

Conditions

  • Diffuse Large B Cell Lymphoma

Interventions

  • RituximabDrug

    Rituximab IV infusion will be administered as per the schedule specified in the respective arm.

  • CyclophosphamideDrug

    Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.

  • DoxorubicinDrug

    Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.

  • VincristineDrug

    Vincristine IV infusion will be administered as per the schedule specified in the respective arm.

  • PrednisoneDrug

    Prednisone PO will be administered as per the schedule specified in the respective arm.

  • OrelabrutinibDrug

    Orelabrutinib PO will be administered as per the schedule specified in the respective arm.

  • LenalidomideDrug

    Lenalidomide PO will be administered as per the schedule specified in the respective arm.

  • DecitabineDrug

    Decitabine IV infusion will be administered as per the schedule specified in the respective arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survivalTime frame: Baseline up to data cut-off (up to approximately 2 years)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.